Search Within

Sham Mailankody

Formats
  1. Meeting Abstract (169)
  2. Journal Article (98)
  3. Research Letter (12)
  4. Review (10)
  5. Correspondence (5)
  6. Editorial (2)
  7. Guidelines (1)
Groups
  1. Center for Hematologic Malignancies (297)
  2. Department of Medicine (297)
  3. Hematologic Malignancies, Division of (297)
  4. Myeloma (297)
  5. Survivorship Research (216)
  6. Hematologic Malignancies Research (212)

More Groups

People
  1. Neha Korde (191)
  2. Alexander Lesokhin (170)
  3. Hani Hassoun (163)
  4. Sergio Giralt (161)
  5. Malin Hultcrantz (158)
  6. Heather Landau (147)

More People

Years
  1. 2025 (13)
  2. 2024 (46)
  3. 2023 (49)
  4. 2022 (44)
  5. 2021 (22)
  6. 2020 (22)

More Years

Publications
  1. Blood (96)
  2. Clinical Lymphoma, Myeloma and Leukemia (46)
  3. Journal of Clinical Oncology (23)
  4. Blood Cancer Journal (12)
  5. JAMA Oncology (12)
  6. Leukemia and Lymphoma (10)

More Publications

Publishers
  1. American Society of Hematology (107)
  2. Elsevier Inc. (71)
  3. Nature Publishing Group (26)
  4. American Society of Clinical Oncology (24)
  5. American Medical Association (18)
  6. Taylor & Francis Group (10)

More Publishers

Results (297)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Patterns of cytokine release syndrome with teclistamab in relapsed/refractory multiple myeloma with or without prior T-cell redirection therapy
    Meeting Abstract

    Hamadeh, I.; Shekarkhand, T.; Rueda, C.; Firestone, R.; Wang, A.; Korde, N.; Hultcrantz, M.; Lesokhin, A.; Mailankody, S.; Hassoun, H.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Bispecific T-cell engager response is driven by pre-treatment CD8+ effector memory cells and inhibited by TIGIT+ Tregs in relapsed/refractory multiple myeloma
    Meeting Abstract

    Firestone, R.; McAvoy, D.; Shekarkhand, T.; Serrano, E.; Hamadeh, I.; Wang, A.; Zhu, M.; Patel, D.; Tan, C. R.; Hultcrantz, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CAR T-cell therapy for multiple myeloma: A clinical practice-oriented review
    Review

    Sadek, N. L.; Costa, B. A.; Nath, K.; Mailankody, S.
    Clinical Pharmacology & Therapeutics (2023)

    Fulltext@MSK | Save
  • Genetic basis of relapse after GPRCSD-targeted CAR T cells
    Research Letter

    Mi, X.; Penson, A.; Abdel-Wahab, O.; Mailankody, S.
    New England Journal of Medicine (2023)

    Fulltext@MSK | Save
  • The role of chimeric antigen receptor T-cell therapy in the era of bispecific antibodies
    Review

    Nath, K.; Mailankody, S.; Usmani, S. Z.
    Hematology/Oncology Clinics of North America (2023)

    Fulltext@MSK | Save
  • A first-in-human phase 1, multicenter, open-label study of CB-011, a next-generation CRISPR-genome edited allogeneic anti-BCMA immune-cloaked CAR-T cell therapy, in patients with relapsed/refractory multiple myeloma (CAMMOUFLAGE trial)
    Meeting Abstract

    Berdeja, J. G.; Martin, T. G.; Rossi, A.; Essell, J. H.; Siegel, D. S. D.; Mailankody, S.; Saini, N.; Holmes, H.; Dhakal, B.; Gasparetto, C. J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • ISAMAR: Multicenter phase II single arm trial of isatuximab (ISA) with/without lenalidomide (LEN) in pts with high risk smoldering multiple myeloma (HRSMM)
    Meeting Abstract

    Manasanch, E. E.; Korde, N.; Lee, H. C.; Patel, K. K.; Becnel, M.; Berrios, D.; Thomas, S. K.; Iyer, S. P.; Mailankody, S.; Amini, B.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies
    Meeting Abstract

    Firestone, R.; Shekarkhand, T.; Patel, D.; Tan, C. R. C.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; Shah, U. A.; Korde, N.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma
    Journal Article

    Tan, C. R.; Derkach, A.; Nemirovsky, D.; Ciardiello, A.; Diamond, B.; Hultcrantz, M.; Hassoun, H.; Mailankody, S.; Shah, U.; Maclachlan, K.; more...
    Blood Cancer Journal (2023)

    Fulltext@MSK | Save
  • Clinical value of second opinions in oncology: A retrospective review of changes in diagnosis and treatment recommendations
    Journal Article

    Lipitz-Snyderman, A.; Chimonas, S.; Mailankody, S.; Kim, M.; Silva, N.; Kriplani, A.; Saltz, L. B.; Sihag, S.; Tan, C. R.; Widmar, M.; more...
    Cancer Medicine (2023)

    Fulltext@MSK | Save